nortrachelogenin has been researched along with Prostatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eklund, P; Eriksson, JE; Holmbom, T; Paul, P; Peuhu, E; Remes, M; Sjöholm, R | 1 |
| Aittokallio, T; Eckerman, C; Holmbom, B; Laajala, TD; Mäkelä, SI; Polari, L; Saarinen, NM; Smeds, A; Yatkin, E | 1 |
2 other study(ies) available for nortrachelogenin and Prostatic Neoplasms
| Article | Year |
|---|---|
The antitumor lignan Nortrachelogenin sensitizes prostate cancer cells to TRAIL-induced cell death by inhibition of the Akt pathway and growth factor signaling.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Furans; Humans; Insulin-Like Growth Factor I; Lignans; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand | 2013 |
Novel Lignan and stilbenoid mixture shows anticarcinogenic efficacy in preclinical PC-3M-luc2 prostate cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Furans; Heterografts; Humans; Lignans; Male; Mice; Pinus sylvestris; Plant Extracts; Prostatic Neoplasms; Stilbenes; TNF-Related Apoptosis-Inducing Ligand | 2014 |